Management of chronic obstructive pulmonary disease (COPD) suffers not only from a lack of effective therapies but also from an inability to track the disease’s progression. Spirometers that measure how much air patients can displace using their lungs are the “gold standard,” but that standard is pretty poor in helping to predict how COPD will develop. Researchers at Johns Hopkins University have now used special nanoparticles to test the mucus of COPD patients, which may be an excellent biomarker for…
